For the quarter ended September 2025, Steris (STE) reported revenue of $1.46 billion, up 9.9% over the same period last year. EPS came in at $2.47, compared to $2.14 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.43 billion, representing a surprise of +2.31%. The company delivered an EPS surprise of +3.78%, with the consensus EPS estimate being $2.38.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Healthcare: $1.03 billion versus $1.01 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
- Revenues- Healthcare Products- Consumables: $374.2 million versus $357.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
- Revenues- Healthcare Products- Capital Equipment: $259.4 million compared to the $268.96 million average estimate based on three analysts. The reported number represents a change of +3.9% year over year.
- Revenues- Healthcare Products- Service: $400.1 million versus $374.76 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.4% change.
- Revenues- Life Sciences: $145 million versus $137.24 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.3% change.
- Revenues- Applied Sterilization Technologies (AST): $281.5 million compared to the $281.02 million average estimate based on three analysts. The reported number represents a change of +9.7% year over year.
- Revenues- Life Sciences- Service: $35.8 million versus $36.79 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
- Revenues- Life Sciences- Capital Equipment: $31.9 million versus $27.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +38.6% change.
- Revenues- Life Sciences- Consumables: $77.2 million versus $71.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
- Operating income / (loss)- Healthcare: $259.5 million compared to the $239.46 million average estimate based on two analysts.
- Operating income / (loss)- Corporate and Other: $-109.9 million versus the two-analyst average estimate of $-106.78 million.
- Operating income / (loss)- Applied Sterilization Technologies (AST): $127.6 million versus $132.54 million estimated by two analysts on average.
View all Key Company Metrics for Steris here>>>
Shares of Steris have returned +0.1% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
STERIS plc (STE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
